Abstract: Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Methods and devices for diagnosing, monitoring, or determining kidney damage in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney damage using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Methods and devices for diagnosing, monitoring, or determining kidney damage in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney damage using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Methods and devices for diagnosing, monitoring, or determining a renal disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining a renal disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Devices for diagnosing, monitoring, or determining a renal disorder in a mammal are described. In particular, devices for diagnosing, monitoring, or determining a renal disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Abstract: Provided are methods for the detection and diagnosis of a predisposition for developing diabetes. The methods are based on the discovery that abnormal levels of the selected analyte in biological samples, typically blood samples, of patients who are at risk are supportive of a diagnosis of a predisposition for developing diabetes. At least one new biomarker for a predisposition for diabetes is thus disclosed, IGF-1. Other important biomarkers for diabetes are described, including but not limited to ZAG, clusterin, corticosteroid-binding globulin, lumican, and serotransferrin. Kits containing reagents to assist in the analysis of biological samples are also described.

Abstract: Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack.

Abstract: Methods for characterizing immune diseases are provided which include exposing a sample of biological fluid from a patient to a pooled population of particles, wherein a first subset of particles is bound to a reactant that binds an antibody and a second subset of particles is bound to a reactant that binds an antigen. The methods further include determining a ratio of measured amounts of the antibody and the antigen in the sample. In some cases, the ratio is compared to one or more standard ratios representing differing states of the disease to determine a state of the disease within the patient. In other embodiments, the steps of exposing and determining a ratio of antibody to antigen are repeated for one or more additional samples of biological fluid taken from the patient. In such cases, at least two ratios are compared to analyze a progression of the disease.

Abstract: The invention relates to methods of characterizing autoimmune diseases by detecting and measuring at least one analyte using multiplexed assay systems. According to one embodiment, a target is detected and measured by different bead sets having different reactants. According to another approach the ratio of self-antigen to autoantibody is measured by exposing a sample suspected of containing self-antigen and autoantibody to a bead set associated with monoclonal antibody specific for the self-antigen and a bead set associated with the self-antigen.

Abstract: The invention relates to methods of characterizing autoimmune diseases by detecting and measuring at least one analyte using multiplexed assay systems. According to one embodiment, a target is detected and measured by different bead sets having different reactants. According to another approach the ratio of self-antigen to autoantibody is measured by exposing a sample suspected of containing self-antigen and autoantibody to a bead set associated with monoclonal antibody specific for the self-antigen and a bead set associated with the self-antigen.

Abstract: The present invention relates to the substantial elimination of errors attributable to carryover microspheres, doublets, or misclassification of microsphere subsets. The present invention is based upon passing a sufficient minimum number microspheres through the flow analyzer during an assay run.

Abstract: The invention relates to methods of characterizing autoimmune diseases by detecting and measuring at least one analyte using multiplexed assay systems. According to one embodiment, a target is detected and measured by different bead sets having different reactants. According to another approach the ratio of self-antigen to autoantibody is measured by exposing a sample suspected of containing self-antigen and autoantibody to a bead set associated with monoclonal antibody specific for the self-antigen and a bead set associated with the self-antigen.